A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Participants

NCT02398591 | Completed Phase 1

• 3 other identifiers: CR10700353718678RSV10042014-005410-36
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of three dosages (250, 500, and 1000 milligram \[mg\], or maximum tolerated dose \[MTD\]) of JNJ 53718678 when administered as single dose in fasting conditions in healthy Japanese adult participants in 3 cohorts.

Conditions

Healthy

Keywords

Healthy; JNJ 53718678

Outcome Measures

Primary Outcomes (12)

• Maximum Observed Plasma Concentration (Cmax)

  The Cmax is the maximum observed plasma concentration.

  Up to 72 hours post dose

• Time to Reach Maximum Observed Plasma Concentration (Tmax)

  The Tmax is defined as actual sampling time to reach maximum observed JNJ 53718678 concentration.

  Up to 72 hours post dose

• Time to Last Quantifiable Plasma Concentration (Tlast)

  The Tlast is the time to last observed quantifiable plasma concentration.

  Up to 72 hours post dose

• Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0-last])

  The AUC (0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.

  Up to 72 hours post dose

• Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])

  The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.

  Up to 72 hours post dose

• Apparent Initial Elimination Rate Constant (lambda [alpha])

  Apparent initial elimination rate constant, determined by linear regression of the data points within the first elimination phase of the ln-linear plasma concentration-time curve.

  Up to 72 hours post dose

• Elimination Rate Constant (Lambda[z])

  Lambda(z) is first-order elimination rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.

  Up to 72 hours post dose

• Apparent Initial Elimination Half-life (t1/2[alpha])

  Apparent initial elimination half-life is calculated as 0.693/lambda(alpha).

  Up to 72 hours post dose

• Elimination Half-Life (t1/2)

  The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).

  Up to 72 hours post dose

• Total Apparent Clearance (CL/F)

  Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

  Up to 72 hours post dose

• Apparent Volume of Distribution (Vd/F)

  Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after subcutaneous dose (Vd/F) is influenced by the fraction absorbed.

  Up to 72 hours post dose

• Number of Participants With Adverse Events

  An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

  From sign of informed consent up to end of study (Day 14)

Study Arms (3)

JNJ 53718678 250 milligram (mg)

EXPERIMENTAL

Participants will receive either single oral dose of 250 mg of JNJ 53718678 or matching placebo on Day 1.

Drug: JNJ 53718678; Drug: Placebo

JNJ 53718678 500 mg

EXPERIMENTAL

Participants will receive either single oral dose of 500 mg of JNJ 53718678 or matching placebo on Day 1.

Drug: JNJ 53718678; Drug: Placebo

JNJ 53718678 1000 mg

EXPERIMENTAL

Participants will receive either single oral dose of 1000 mg of JNJ 53718678 or matching placebo on Day 1.

Drug: JNJ 53718678; Drug: Placebo

Interventions

JNJ 53718678 DRUG

JNJ 53718678 will be orally administered once in a dose of 250, 500 or 1000 mg on Day 1.

JNJ 53718678 1000 mg; JNJ 53718678 250 milligram (mg); JNJ 53718678 500 mg

Placebo DRUG

Placebo matching to JNJ 53718678 will be orally administered once on Day 1.

JNJ 53718678 1000 mg; JNJ 53718678 250 milligram (mg); JNJ 53718678 500 mg

Eligibility Criteria

• Age: 20 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Participant must be a Japanese participant who has resided outside Japan for no more than 5 years and whose parents and grandparents are Japanese as determined by participant's verbal report
• Participant must be healthy on the basis of a medical evaluation that reveals the absence of any clinically relevant abnormality and includes a physical examination (including height and body weight measurement and skin examination), medical history, vital signs (body temperature, systolic blood pressure, diastolic blood pressure, pulse rate, orthostatic hypotension, and respiratory rate), and the results of blood biochemistry, blood coagulation and hematology tests, a urinalysis, and a hematest performed at Screening, on Day -1, or Day 1 pre-dose, whichever is applicable. If there are abnormalities, the participant may be included only if the Investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participant's source documents and initialed by the Investigator
• Female participants must be of non-childbearing potential: postmenopausal for at least 2 years (amenorrheal for at least 2 years and a serum follicle stimulating hormone \[FSH\] level greater than \[\>\] 40 international unit per liter \[IU/L\] or milli IU per milliliter \[mIU/mL\]), or surgically sterile (have had a total hysterectomy, bilateral oophorectomy, or bilateral tubal ligation/bilateral tubal clips without reversal operation), or otherwise incapable of becoming pregnant
• Participant must be a non-smoker for at least one month prior to Screening
• Participant must have a body mass index (BMI) (weight \[kilogram{kg}\]/height\^2 \[meter\^2\]) between 18 and 30 kg/m\^2 (inclusive), and body weight not less than 50 kg

You may not qualify if:

• Participant has a history of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, hepatic or renal insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the Investigator considers should exclude the subject or that could interfere with the interpretation of the study results
• Participant with any history of clinically significant skin disease such as, but not limited to, dermatitis, eczema, drug rash, psoriasis, food allergy, and urticaria
• Clinically significant abnormal physical examination, vital signs, or 12 lead electrocardiogram (ECG) at Screening, on Day -1 (physical examination only), and pre-dose on Day 1, as deemed appropriate by the Investigator
• Participants with lack of good/reasonable venous access
• Participants with a past history of heart arrhythmias (extrasystoli, tachycardia at rest) or, history of risk factors for Torsade de Pointes syndrome (for example, hypokalemia, family history of long QT Syndrome

Sponsors & Collaborators

• Janssen Sciences Ireland UC: lead

Study Sites (1)

Unknown Facility

Harrow, United Kingdom

Location

MeSH Terms

Interventions

JNJ-53718678

Study Officials

• Janssen Sciences Ireland UC Clinical Trials

  Janssen Sciences Ireland UC

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 20, 2015
• First Posted: March 25, 2015
• Study Start: April 1, 2015
• Primary Completion: July 15, 2015
• Study Completion: July 15, 2015
• Last Updated: July 11, 2017

Record last verified: 2017-07

Locations

GB (1)